Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | CDK4 | P11802 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6594423 | 0.85 | ABL1 (0.62) | PRKCDABL1PRKCAPLK1CDK2 | |
| SCHEMBL5104939 | 0.84 | PRKCD (0.51) | PRKCDABL1EGFRPRKCAKDR | |
| SCHEMBL27536219 | 0.84 | CDK2 (0.46) | PRKCDABL1EGFRPRKCAKDR | |
| SCHEMBL4867623 | 0.83 | ABL1 (0.56) | PRKCDABL1EGFRPRKCAKDR | |
| SCHEMBL5096290 | 0.83 | PRKCD (0.53) | PRKCDABL1EGFRPRKCAKDR | |
| SCHEMBL6103355 | 0.82 | CDK2 (0.69) | CDK2GSK3BCDK4CDK1IKBKB | |
| SCHEMBL5105343 | 0.78 | CDK2 (0.69) | PRKCDABL1EGFRPRKCAKDR | |
| SCHEMBL6599115 | 0.77 | CDK2 (0.58) | CDK2GSK3BCDK4CCNE1CDK1 | |
| SCHEMBL6593229 | 0.77 | IKBKB (0.61) | ABL1CDK2CDK4CDK1IKBKB | |
| SCHEMBL6593493 | 0.75 | KDR (0.53) | PRKCDABL1EGFRPRKCAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1269813-C | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| US-6969714-B2 | Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2002020512-A9 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| CN-1452620-A | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (CH) | 2003-10-29 | — | — | CN | disclosed |
| EP-1351958-A1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002020512-A1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | MKI67, CCNI, CCNT1 | PRKCD 811/4885ABL1 173/4885EGFR 2254/4885 |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | CCNI, TYMP, MKI67 | PRKCD 560/4885ABL1 822/4885EGFR 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.